$CNBX

Cannabis Stock Gainers And Losers From May 1, 2025 - FLUENT (OTC:CNTMF), CNBX Pharmaceuticals (OTC:CNBX)

Maple Leaf Green World MGWFF shares closed up 83.67% at $0.03 Elixinol Wellness ELLXF shares closed up 77.11% at $0.01 4Front Ventures FFNTF shares closed up 45.00% at $0.00 1933 Industries TGIFF shares closed up 42.86% at $0.01 SOL Global Investments SOLCF shares closed up 19.84% at $0.09

Original reporting
Benzinga · Benzinga Insights
Published May 1, 2025, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 2, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cannabis Stock Gainers And Losers From May 1, 2025 - FLUENT (OTC:CNTMF), CNBX Pharmaceuticals (OTC:CNBX) — source image
Decision brief

The 30-second read

$CNBXBullishMed
01

Why it matters

The recent gains across multiple tickers suggest increased investor confidence, possibly influenced by industry developments or favorable regulatory news.

02

Market read

The sector is currently experiencing bullish momentum, with multiple companies showing significant share price increases, indicating a positive short-term trading environment.

03

What to watch

Regulatory changes, market saturation, or macroeconomic factors could impact the sustainability of current bullish trends; technical indicators and broader market conditions should be monitored.

Timing: Short-term, within days to weeks

Background

The cannabis industry has experienced significant volatility and growth, with recent positive news and market sentiment driving share price surges.

Company-level read

Ticker impact

$CNBXBullishMedium confidence
Context

High relevance due to recent gains and inclusion in the top gainers list.

Expected impact

Possible continuation of upward trend in the near term.

Evidence & confidence

Strong recent gains and bullish sentiment support further movement, but technical confirmation needed.

$CRBPBullishLow confidence
Context

Low relevance with a 19.90% relevance score; minimal impact on overall market sentiment.

Expected impact

Likely minimal impact on broader market; focus on more relevant tickers.

Evidence & confidence

Lower relevance suggests limited market influence; technical analysis required for actionable insights.

Market effects

Positive sentiment in cannabis sector may boost related industries such as retail, manufacturing, and life sciences

Potential uplift in North American cannabis markets, especially in regions with legal reforms

Limited; primarily regional effects with some influence on global cannabis industry sentiment

Counterpoint

The recent gains may be driven by speculative trading or short-term hype, risking a correction or pullback in the near future.

Key entities

  • Maple Leaf Green World

    Cannabis cultivation and production company.

  • Elixinol Wellness

    CBD and wellness product manufacturer.

  • 4Front Ventures

    Cannabis retailer and producer.

  • 1933 Industries

    Cannabis consumer products.

  • SOL Global Investments

    Invests in cannabis and related industries.

Related articles

$CRBPMed

Corbus Pharmaceuticals Holdings, Inc. (CRBP): Results of Operations and Financial Condition

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last

$CRBPHighAI 9/10

Corbus Pharmaceuticals Announces Updated Data From CRB-701 Study, Stock Down In Pre-Market

Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.

$AVEXMed

AVEX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages AVEX Investors with Losses to Contact the Firm

AEVEX Corp. (NYSE: AVEX) faces a securities fraud class action lawsuit over alleged misstatements regarding a secondary public offering. The lawsuit covers investors who bought shares between April 17, 2026, and June 4, 2026. The stock dropped 16% on June 2, 2026, and 7% on June 5, 2026, following disclosures about the offering. Investors have until October 20, 2026, to seek lead plaintiff status.

$BAHighAI 9/10

US okays $5.75 billion munitions, engines sale to Saudi Arabia

The US State Department approved a $5 billion sale of Joint Direct Attack Munitions-Extend Range and a $750 million sale of AGT-1500 engines to Saudi Arabia. Boeing and Honeywell are the principal contractors, respectively. The sales aim to enhance Saudi Arabia's defense capabilities and regional interoperability, according to the State Department.